Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab)
- Product Code: 140408
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Used in cancer immunotherapy to block the PD-1 receptor on T-cells, enhancing the immune system's ability to detect and destroy tumor cells. It is applied in treating various malignancies, including melanoma, non-small cell lung cancer, and other solid tumors. By inhibiting the PD-1 immune checkpoint pathway, it helps restore anti-tumor immune responses that cancer cells often suppress. Currently utilized in clinical trials and therapeutic regimens, often in combination with other immunotherapies or treatments like chemotherapy and radiation.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 50μg | 10-20 days | £113.85 |
+
-
|
Anti-PDCD1 / PD-1 / CD279 Reference Antibody (spartalizumab)
Used in cancer immunotherapy to block the PD-1 receptor on T-cells, enhancing the immune system's ability to detect and destroy tumor cells. It is applied in treating various malignancies, including melanoma, non-small cell lung cancer, and other solid tumors. By inhibiting the PD-1 immune checkpoint pathway, it helps restore anti-tumor immune responses that cancer cells often suppress. Currently utilized in clinical trials and therapeutic regimens, often in combination with other immunotherapies or treatments like chemotherapy and radiation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
£0.00
£0.00
Total :